Indivior's addiction therapy passes Phase III test

Indivior plc (LSE:INDV) said both tested regimens of RBP-6000 met the primary endpoint of a Phase III study to treat opioid use disorder. The company said FDA could approve the buprenorphine formulation as early as 4Q17, if the agency grants the candidate Priority Review.

Both six-month regimens significantly improved the percentage of patient urine samples negative for opioids, combined with self-reports negative for illicit opioid use, from week five to week 24 vs. placebo (p<0.0001 for both regimens). ...